RxDoctor Payments Data

Mandira Rajkarnikar, MD

Family Medicine · Lenexa, KSNPI 1205196136

Payments from drug & device makers

$10,920in general payments, 2019–2025

Across 639 payments — averaging $17.09 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • Lilly USA, LLC$1K
  • Novo Nordisk$880
  • Pfizer$773
  • Amgen$752
  • AstraZeneca$699
  • plus $5K from 42 others

What the payments were for

  • Food & beverage$10,914100%
  • Education$60%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$10,920 in reported general payments places this provider in the 95th percentile of 1,469 family medicine providers in Kansas.

See all family medicine providers in Kansas

Medicare billing

Part B allowed, 2024
$198,782
Medicare patients
200
Services billed
6,780

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide53$68,409
Trelegy ElliptaFluticasone/Umeclidin/Vilanter64$59,967
EliquisApixaban52$55,360
JardianceEmpagliflozin35$49,320
XareltoRivaroxaban34$31,028
TrulicityDulaglutide11$23,992
MyrbetriqMirabegron27$20,699
MounjaroTirzepatide15$18,963
Breo ElliptaFluticasone/Vilanterol16$13,584
Tresiba Flextouch U-200Insulin Degludec14$8,363
Atorvastatin Calcium810$5,516
Fluticasone-SalmeterolFluticasone Propion/Salmeterol26$3,754
Levothyroxine Sodium376$3,088
DuleraMometasone/Formoterol11$3,087
Gabapentin156$2,871

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta, Breo Ellipta$373$73,55180 claims
Novo NordiskOzempic$880$68,40953 claims
PfizerEliquis$773$55,36052 claims
Boehringer IngelheimJardiance$320$49,32035 claims
Lilly USA, LLCTrulicity, Mounjaro$1,330$42,95526 claims
Johnson & JohnsonXarelto$697$31,02834 claims
Astellas Pharma US IncMyrbetriq$79$20,69927 claims
MerckDulera$209$3,08711 claims
AbbVieSynthroid$1,415$1,99431 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,469 family medicine providers in Kansas.

Other family medicine in Lenexa

See the full list for Kansas

Where these figures come from

Is this you, or does something look wrong? →